Comparison

GHK vs
GHK-Cu

One three-amino-acid peptide, in two different chemical forms. Here is what the cited studies and the status records do—and do not—let us compare.

Short answerCompound research · 7 min read · Updated 21 Nov 2026

GHK is the copper-free tripeptide glycine–histidine–lysine; GHK-Cu is that peptide complexed with copper(II). They are related chemical forms, not interchangeable names. The studies summarized here used different models: cultured human skin models for GHK and a small randomized study of a GHK-Cu-containing skincare regimen. They do not establish which form is preferable.

Key takeaways

  • GHK is glycine–histidine–lysine; GHK-Cu is its copper(II) complex.
  • The GHK study summarized here used cultured human keratinocytes and a skin-equivalent model, not human participants.
  • A 2006 randomized study of a GHK-Cu-containing skincare regimen had 13 completers; material sold online is not the formulation tested.
  • FDA’s 503A list has an entry for GHK-Cu, for certain routes only, and none for GHK without copper; the Poisons Standard October 2026 names neither.
  • Neither form is named on WADA’s 2026 or 2027 List; WADA says a peptide not specifically named “may still be prohibited”.

01GHK vs GHK-Cu in one table

This comparison separates the two chemical forms from what the cited study and status records establish. Regulatory findings are dated and scoped to the records checked.

QuestionGHK, copper-freeGHK-Cu
IdentityGlycine–histidine–lysine (GHK), a three-amino-acid peptideGHK complexed with copper(II)
Evidence tier and modelT4: cultured human keratinocytes and a skin-equivalent model, in a 2012 laboratory studyT1, small: randomized human study of skincare regimens with or without GHK-Cu; 13 completed
Human-participant data in the studies cited hereThe 2012 study used human cells and a skin-equivalent model, not human participants13 participants completed the 2006 randomized study; it assessed skin measures and questionnaires after laser resurfacing
United States, checked hereFDA’s 503A nominations list (updated 14 May 2026) has no entry for GHK without copper (searched 21 Nov 2026)FDA’s 503A list places it in Category 1, “Bulk Drug Substances Under Evaluation”, for certain routes of administration only
United Kingdom, checked hereThe emc medicines database returned no results for GHK (21 Nov 2026); it is not the full UK registerNo results for GHK, copper tripeptide or prezatide in the same database (21 Nov 2026)
Australia, checked hereThe TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK has no entry by name in the Poisons Standard October 2026; we draw no scheduling conclusion of our ownThe TGA statement on the left applies to peptide products generally. GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own
Sport, WADA 2026 and 2027 ListsNot named. WADA says a peptide not specifically named “may still be prohibited”Not named, as on the left

02What changes when copper is present?

GHK names the three-amino-acid peptide: glycine, histidine, and lysine. GHK-Cu names a copper(II) complex of that peptide. The names are related, but the copper complex is a different chemical form. They should not be treated as interchangeable labels for interpreting a study or describing what a sample contains.

That chemical distinction is narrower than a claim about what either form does. The presence of copper tells you how the compounds differ by name; it does not, by itself, establish a difference in human outcomes, safety, or product quality. To make a performance comparison, research would need to compare the two forms under comparable conditions. The studies summarized on this page do not do that.

GHK

Three amino acids

The name refers to glycine, histidine, and lysine joined in one peptide.

GHK-Cu

Copper(II) complex

The added copper distinguishes this chemical form from copper-free GHK.

Evidence

Separate study models

The studies summarized here do not directly compare the two forms.

03What did the cited studies measure?

GHK, copper-free. A 2012 laboratory study used cultured normal human keratinocytes and a skin-equivalent model. It assessed cell characteristics and markers in those models, and its authors concluded that copper-free GHK “showed similar effects with copper-GHK”; the abstract describes experiments with copper-free GHK and cites the group’s earlier copper-GHK work. This is T4 evidence: a human-cell model is not a study in human participants, and it is not evidence of an effect in people.

GHK-Cu. Miller and colleagues’ 2006 randomized study compared skincare regimens with or without GHK-Cu after carbon-dioxide laser resurfacing. Thirteen participants completed it. Researchers assessed redness over time, skin appearance, and questionnaire responses. On objective measures it found no statistically significant difference between groups: not in how soon redness resolved, and not in evaluators’ ratings of wrinkles or skin quality. This is a small human study, not a head-to-head test of copper-free GHK against GHK-Cu. Material sold online is not the formulation tested in that study.

Study design is not a verdict

A randomized design is useful evidence, but a small study of one formulation does not rank every product sold under a related name.

Keep the test material in view

Study findings describe what was tested in that study. They do not confirm the contents or performance of another formulation.

If you searched “ghk basic vs ghk-cu,” the key distinction is chemical identity, not a ranking from these studies. “GHK basic” is not a name we found in PubMed (searched 21 November 2026) or in the regulator documents cited here; this page compares GHK without copper and GHK-Cu. For more context on study populations and limits, see our GHK-Cu research guide.

04What do the status records say?

United States. FDA’s 503A list, updated 14 May 2026, places GHK-Cu in Category 1, “Bulk Drug Substances Under Evaluation”, for certain routes of administration only, and FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027. The list has no entry for GHK without copper (searched 21 November 2026). We do not infer one form’s status from the other’s.

Australia. The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” The Poisons Standard October 2026 names neither GHK nor GHK-Cu; it has group entries for copper compounds. We draw no scheduling conclusion of our own.

United Kingdom. The emc medicines database returned no results for GHK, copper tripeptide or prezatide (21 November 2026). It is not the full UK register.

Sport. Neither form is named on WADA’s 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”.

To see what a report for a given lot must show, read how to read a certificate of analysis.

05What we don’t know

Direct comparison

The two studies described here do not establish whether either form is preferable to the other.

Human evidence for GHK

The cited copper-free GHK paper is a cell and skin-equivalent study, not a participant study.

Product-level status

The status findings above do not settle the legal status of a specific product, or the status of copper-free GHK.

These limits are why the page does not name a winner. The two substances have different chemical identities, the studies use different models, and the status records answer narrow questions about specific lists and jurisdictions. None of those facts provides a basis for a general “better” verdict.

This is a plain-English summary of studies and public records checked on 21 November 2026. It is not legal or medical advice.

RefSources

  1. Miller TR, Wagner JD, Baack BR, Eisbach KJ. [Randomized study of a GHK-Cu-containing skincare formulation after laser resurfacing]. Archives of Facial Plastic Surgery, 2006. journals.sagepub.com/doi/10.1001/archfaci.8.4.252
  2. Choi HR, Kang YA, Ryoo SJ, et al. [Laboratory study of copper-free GHK in cultured human keratinocytes and a skin-equivalent model.] Journal of Peptide Science, 2012;18(11):685–690. PMID 23019153 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/23019153/
  3. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; read 21 Nov 2026. www.fda.gov/media/94155/download
  4. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation, commenced 1 Oct 2026; text searched 21 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  5. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  6. Electronic medicines compendium (emc). Searches for GHK, copper tripeptide and prezatide: “No search results” (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=GHK
  7. PubMed searches for the name “GHK basic”, quoted and unquoted: no records. Database searches, 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%22GHK+basic%22%5Btiab%5D
  8. World Anti-Doping Agency. Prohibited List 2026. International Standard, in force 1 January 2026; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  9. World Anti-Doping Agency. Prohibited List 2027. International Standard, in force 1 January 2027; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  10. World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes (S0, peptides). Explanatory note; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…
  11. World Anti-Doping Agency. The Prohibited List (“The List is updated at least annually”; “If you cannot find a Substance or Method listed, please verify its status with your Anti-Doping Organization”). Web page, read 21 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Are GHK and GHK-Cu the same molecule?

They are related, but not the same chemical form. GHK is glycine–histidine–lysine; GHK-Cu is that peptide complexed with copper(II).

What human evidence is cited for copper-free GHK?

The cited 2012 study used cultured human keratinocytes and a skin-equivalent model. Those are laboratory models, not human participants.

What did the 2006 GHK-Cu study assess?

It was a randomized study of skincare regimens with or without GHK-Cu after laser resurfacing. Thirteen participants completed it; researchers assessed redness, skin appearance, and questionnaire responses.

What does FDA’s Category 1 listing for GHK-Cu mean?

FDA labels Category 1 “Bulk Drug Substances Under Evaluation”: substances nominated for its 503A compounding list that it is still evaluating. GHK-Cu is there for certain routes of administration only (list updated 14 May 2026); GHK without copper has no entry.

Does WADA name GHK or GHK-Cu?

No. Neither is named on the 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”, and that a substance not found should be checked with your anti-doping organisation.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page